The success of monoclonal antibodies as a therapeutic class for cancer has given rise to the development of various types of therapeutic antibodies, including antibody-drug conjugates, intracellular antibodies, conditionally-active biologics, bispecifics, multi-specifics and multi-valent antibodies, etc. At PEGS Europe's inaugural Antibody-Based Cancer Therapies conference, we will showcase the latest and hottest in these therapeutic approaches, and explore the molecules' mechanisms, engineering, as well as preclinical to clinical translation.